NYSE:CBM - Cambrex Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$55.15 -0.10 (-0.18 %)
(As of 07/16/2018 02:23 AM ET)
Previous Close$55.15
Today's Range$54.85 - $55.8490
52-Week Range$42.55 - $62.30
Volume142,355 shs
Average Volume349,262 shs
Market Capitalization$1.82 billion
P/E Ratio17.40
Dividend YieldN/A
Beta2.27
Cambrex logoCambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:CBM
CUSIP13201110
Phone201-804-3000

Debt

Debt-to-Equity RatioN/A
Current Ratio5.04
Quick Ratio3.90

Price-To-Earnings

Trailing P/E Ratio17.40
Forward P/E Ratio20.20
P/E Growth1.35

Sales & Book Value

Annual Sales$534.46 million
Price / Sales3.40
Cash Flow$4.2164 per share
Price / Cash13.08
Book Value$16.62 per share
Price / Book3.32

Profitability

EPS (Most Recent Fiscal Year)$3.17
Net Income$102.45 million
Net Margins18.69%
Return on Equity21.00%
Return on Assets15.20%

Miscellaneous

Employees1,228
Outstanding Shares32,960,000
Market Cap$1,817.69

The Truth About Cryptocurrencies

Cambrex (NYSE:CBM) Frequently Asked Questions

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) announced its earnings results on Thursday, May, 3rd. The biotechnology company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.22. The biotechnology company earned $141.10 million during the quarter, compared to the consensus estimate of $104.44 million. Cambrex had a return on equity of 21.00% and a net margin of 18.69%. The firm's revenue for the quarter was up 34.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.68 EPS. View Cambrex's Earnings History.

When is Cambrex's next earnings date?

Cambrex is scheduled to release their next quarterly earnings announcement on Friday, August, 3rd 2018. View Earnings Estimates for Cambrex.

What guidance has Cambrex issued on next quarter's earnings?

Cambrex issued an update on its FY18 earnings guidance on Thursday, May, 3rd. The company provided earnings per share guidance of $2.80 to $3.03 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.90.

What price target have analysts set for CBM?

3 equities research analysts have issued twelve-month target prices for Cambrex's stock. Their predictions range from $60.00 to $60.00. On average, they expect Cambrex's stock price to reach $60.00 in the next year. This suggests a possible upside of 8.8% from the stock's current price. View Analyst Ratings for Cambrex.

What is the consensus analysts' recommendation for Cambrex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Cambrex's key competitors?

Who are Cambrex's key executives?

Cambrex's management team includes the folowing people:
  • Mr. Steven M. Klosk, Pres, CEO & Director (Age 61)
  • Mr. Tom G. Vadaketh, Exec. VP & CFO (Age 55)
  • Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 52)
  • Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 40)
  • Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy (Age 52)

Has Cambrex been receiving favorable news coverage?

Headlines about CBM stock have been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cambrex earned a daily sentiment score of 0.05 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 44.47 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Cambrex's major shareholders?

Cambrex's stock is owned by many different of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.41%) and Confluence Investment Management LLC (0.28%). Company insiders that own Cambrex stock include Gregory Sargen, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh and Steven M Klosk. View Institutional Ownership Trends for Cambrex.

Which institutional investors are selling Cambrex stock?

CBM stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex.

Which institutional investors are buying Cambrex stock?

CBM stock was acquired by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC. View Insider Buying and Selling for Cambrex.

How do I buy shares of Cambrex?

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cambrex's stock price today?

One share of CBM stock can currently be purchased for approximately $55.15.

How big of a company is Cambrex?

Cambrex has a market capitalization of $1.82 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.

How can I contact Cambrex?

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]


MarketBeat Community Rating for Cambrex (NYSE CBM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  333
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.